- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01251406
Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)
A Randomized, Parallel, Placebo-controlled, Double-blind Phase IIa Study of Efficacy and Safety of Recombinant Human Neuregulin-1 (Neucardin) in Subjects With Stable Chronic Heart Failure
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized, parallel, placebo-controlled, double-blind, multi-center study will assess the safety and efficacy of rhNRG-1 also known as Neucardin as a treatment for stable chronic heart failure.
A total of 120 subjects, who have chronic heart failure with a NYHA classification of II or III, and are on a stable regimen of ACEI/angiotensin receptor blocker (ARB), beta-blocker, and/or diuretic for at least 3 months prior to receiving study medication and anticipated to remain on the stable regimen through the treatment period can enroll as per specific inclusion and exclusion criteria.
Subjects will be hospitalized for 10 days during the treatment period and will be infused subcutaneously with rhNRG-1 or placebo.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- University of California, San Diego
-
Los Angeles, California, United States, 90033
- Metabolic Clinic and Research Center
-
Los Angeles, California, United States, 90033
- USC Cardiovascular Division
-
Tustin, California, United States, 92780
- Orange County Research Center
-
-
Colorado
-
Denver, Colorado, United States, 80045
- University of Colorado Denver
-
-
Florida
-
Clearwater, Florida, United States, 33756
- Clearwater Cardiovascular & Interventional Consultants, MD, PA
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Louisiana
-
Kenner, Louisiana, United States, 70065
- MedPharmics, LLC.
-
Metairie, Louisiana, United States, 70006
- Benchmark Research
-
-
Texas
-
Houston, Texas, United States, 77002
- East Texas Cardiology
-
Plano, Texas, United States, 75075
- The Medical Center of Plano
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Sentara Cardiovascular Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years.
- Male or female subjects.
- Have chronic heart failure defined as NYHA classification of II or III.
- Be on a stable regimen of ACEI/ARB and/or beta-blocker 3 months prior to receiving study medication and are expected to remain on a stable HF medication regime throughout the duration of the trial.
- Left ventricular ejection fraction (LVEF) of < 35% as determined at screening by 2-D echocardiography.
- Is able to understand and provide informed consent.
- If subject has dilated cardiomyopathy, ischemic heart disease or corrected valvular heart disease, and had surgery to repair or replace value, the surgery must have been performed 3 months prior to receiving study medication and the surgical area is functioning normally.
- Proper birth control must be used at least 3 weeks prior to the study (women only), during the infusion period of study drug (men and women), 4-weeks after study drug administration (men and women) and the remaining 11 months in the study follow-up (women). Women must have a negative pregnancy test at screening.
- No greater than mild pericardial effusion < 0.5 cm on echocardiography (roughly corresponds to < 100 mL).
- Have an implantable cardioverter-defibrillator (ICD). The ICD should have been implanted at least 3 months prior to receiving study medication. Patients should undergo interrogation of their ICDs between 1 and 7 days before randomization to drug for the previous thirty (30) days. This interrogation would include surveillance for ventricular arrhythmias as well as assessment of ICD discharge(s) and/or anti-tachycardia pacing.
Exclusion Criteria:
- Has chronic heart failure classified as NYHA Class I or IV.
- Has a history of any malignancy or positive test as specified in the pre-cancer screening.
- Have other conditions which in the opinion of the investigator preclude participation in the study, e.g. serious co-morbidity, known or suspected substance abuse or non-compliance.
- Has a body weight >350lbs.
- Has had any cause hospitalization 30 days prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Subcutaneous administration for daily for 8 hours a day for 10 days
|
Daily subcutaneous administration for 8 hours a day for 10 days
Other Names:
|
Experimental: rhNRG-1 Dose 1
Subcutaneous administration for daily for 8 hours a day for 10 days
|
Daily subcutaneous administration for 8 hours a day for 10 days
Other Names:
|
Experimental: rhNRG-1 Dose 2
Subcutaneous administration for 8 hours a day for 10 days
|
Daily subcutaneous administration for 8 hours a day for 10 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in LVEF
Time Frame: 30 days
|
Compared to baseline and placebo
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six (6) minute walk test
Time Frame: Day 30, 90, 180, 365
|
Compared to baseline and placebo
|
Day 30, 90, 180, 365
|
Quality of Life Questionnaire (Kansas City Cardiomyopathy Questionnaire)
Time Frame: Day 30, 90, 180 and 365
|
Compared to baseline and placebo
|
Day 30, 90, 180 and 365
|
NYHA class status
Time Frame: Day 30, 90, 180 and 365
|
Compared to baseline and placebo
|
Day 30, 90, 180 and 365
|
All cause mortality and all cause hospitalization
Time Frame: Days 30, 90, 180 and 365
|
Compared to baseline and placebo
|
Days 30, 90, 180 and 365
|
Change in LVESV and LVEDV
Time Frame: Day 30
|
Compared to baseline and placebo
|
Day 30
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Barry Greenberg, MD, University of California, San Diego
- Principal Investigator: Uri Elkayam, MD, LAC+USC Medical Center
Publications and helpful links
General Publications
- Xu Y, Li X, Liu X, Zhou M. Neuregulin-1/ErbB signaling and chronic heart failure. Adv Pharmacol. 2010;59:31-51. doi: 10.1016/S1054-3589(10)59002-1.
- Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF, Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011 Jan;13(1):83-92. doi: 10.1093/eurjhf/hfq152. Epub 2010 Sep 1.
- Gao R, Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, Zhou M. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010 May 4;55(18):1907-14. doi: 10.1016/j.jacc.2009.12.044.
- Liu X, Gu X, Li Z, Li X, Li H, Chang J, Chen P, Jin J, Xi B, Chen D, Lai D, Graham RM, Zhou M. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006 Oct 3;48(7):1438-47. doi: 10.1016/j.jacc.2006.05.057. Epub 2006 Sep 14.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZS-01-210
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Heart Failure
-
Maastricht University Medical CenterUniversity College Dublin; RWTH Aachen University; Queen's University, BelfastCompletedChronic Heart FailureNetherlands, Germany, Ireland, United Kingdom
-
Wuerzburg University HospitalRecruitingHeart Failure | Chronic Heart Failure | Chronic Heart DiseaseGermany
-
Lithuanian University of Health SciencesCompletedHeart Failure | Chronic Heart Failure | Congestive Heart Failure | Right Ventricular FailureLithuania
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Zensun Sci. & Tech. Co., Ltd.RecruitingChronic Heart FailureChina
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
University of Roma La SapienzaUnknownChronic Heart Failure | Decompensated Heart Failure | Morality
-
University Medicine GreifswaldDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingChronic Heart FailureGermany
-
AquaPass Medical Ltd.CompletedChronic Heart FailureIsrael
-
Zensun Sci. & Tech. Co., Ltd.Terminated
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States